Toxicity of bryostatin-1 on the embryo-fetal development of Sprague-Dawley rats

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 89, Issue 3, 2010, Pages 171-174

  Zhu, Jiangbo ^a   Wan, Xuying ^a   Zhu, Yuping ^a   Ma, Xili ^a   Zheng, Yiwen ^a   Zhang, Tianbao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bryostatin 1; Developmental toxicity; Drug safety; Rat

Indexed keywords

BRYOSTATIN 1; BRYOSTATIN; TERATOGENIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CROWN RUMP LENGTH; EMBRYO RESORPTION; EMBRYOTOXICITY; FEMALE; FETOTOXICITY; FETUS; FETUS DEATH; FETUS DEVELOPMENT; FETUS MALFORMATION; FETUS RESORPTION; FETUS WEIGHT; GESTATION PERIOD; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETON MALFORMATION; SPRAGUE DAWLEY RAT; TERATOGENESIS; WEIGHT GAIN; ANIMAL; CHEMISTRY; DRUG EFFECTS; EMBRYO DEVELOPMENT; ENVIRONMENTAL EXPOSURE; PREGNANCY; TOXICITY; TOXICITY TESTING;

ANIMALIA; BUGULA NERITINA; RATTUS;

ANIMALS; BRYOSTATINS; EMBRYONIC DEVELOPMENT; FEMALE; FETUS; MALE; MATERNAL EXPOSURE; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; TERATOGENS; TOXICITY TESTS;

EID: 77953574650     PISSN: 15429733     EISSN: 15429741     Source Type: Journal    
DOI: 10.1002/bdrb.20229     Document Type: Article

References (26)

1. Abrams ST, Lakum T, Lin K, Jones GM, Treweeke AT, Farahani M, Hughes M, Zuzel M, Slupsky JR. 2007. B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII. Blood 109:1193-1201.
2. Ariyuki F, Ishihara H, Higaki K, Yasuda M. 1982. A study of fetal growth retardation in teratological tests: relationship between body weight and ossification of the skeleton in rat fetuses. Teratology 26:263-267.
3. Bögi K, Lorenzo PS, Szállási Z, Acs P, Wagner GS, Blumberg PM. 1998. Differential selectivity of ligands for the C1a and C1b phorbol ester binding domains of protein kinase Cdelta: possible correlation with tumor-promoting activity. Cancer Res 58:1423.
4. Dawson AB. 1926. A note on the staining of the skeleton of cleared specimens with alizarin red S. Stain Technol 1:123-124.
5. Elgie AW, Sargent JM, Alton P, Peters GJ, Noordhuis P, Williamson CJ, Taylor CG. 1998. Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML. Leuk Res 22:373-378.
6. Gonzalez R, Ebbinghaus S, Henthorn TK, Miller D, Kraft AS. 1999. Treatment of patients with metastatic melanoma with bryostatin-1: a phase II study. Melanoma Res 9:599-606. (Pubitemid 30007780)
7. Grant S, Roberts J, Poplin E, Tombes MB, Kyle B, Welch D, Carr M, Bear HD. 1998. Phase Ib trial of bryostatin-1 in patients with refractory malignancies. Clin Cancer Res 4:611-618. (Pubitemid 28193559)
8. Haas NB, Smith M, Lewis N, Littman L, Yeslow G, Joshi ID, Murgo A, Bradley J, Gordon R, Wang H, Rogatko A, Hudes GR. 2003. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study. Clin Cancer Res 9:109-114. (Pubitemid 36109722)
9. Hayun M, Okun E, Hayun R, Gafter U, Albeck M, Longo DL, Sredni B. 2007. Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro andinananimalmodel. Leukemia 21:1504-1513.
10. Johnson MD, Torri JA, Lippman ME, Dickson RB. 1999. Regulation of motility and protease expression in PKC-mediated induction of MCF-7 breast cancer cell invasiveness. Exp Cell Res 247:105-113.
11. Kraft AS, Smith JB, Berkow RL. 1986. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc Natl Acad Sci USA 83:1334-1338.
12. Kraft AS, Woodley S, Pettit GR, Gao F, Coll JC, Wagner F. 1996. Comparison of the antitumor activity of bryostatins 1, 5, and 8. Cancer Chemother Pharmacol 37:271-278.
13. Manson J, Kang T. 1989. Test methods for assessing female reproductive and developmental toxicology. In: Hayes AW, editor. Principles and methods of toxicology. New York: Raven Press. p 311-359.
14. Mutter R, Wills M. 2000. Chemistry and clinical biology of the bryostatins. Bioorgan Med Chem 8:1841-1860.
15. OECD. 2001. Test Guidance 414. Prenatal Developmental Toxicity Study. In: OECD Guidance for Testing of Chemicals. Paris: Organization for Economic Cooperation and Development.
16. Pettit GR. 1996. Progress in the discovery of biosynthetic anticancer drugs. J Nat Prod 59:812.
17. Propper DJ, Macaulay V, O'Byrne KJ, Braybrooke JP, Wilner SM, Ganesan TS, Talbot DC, Harris AL. 1998. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer 78:1337.
18. Roberts JD, Smith MR, Feldman EJ, Cragg L, Grant S. 2002. Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Clin Lymphoma 3:184-188. (Pubitemid 36113692)
19. Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, Honeycutt C, Thune R, Padavic-Shaller K, Carter WH, Ramakrishnan V, Murgo AJ, Grant S. 2006. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma. Clin Cancer Res 12:5809-5816.
20. Rochford R, Feuer G, Orem J, Banura C, Katongole-Mbidde E, Mwanda WO, Moormann A, Harrington WJ, Remick SC. 2005. Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma. East Afr Med J 82(Suppl 9):S155-S160. (Pubitemid 43844879)
21. Stuckhart JL, Poppe SM. 1984. Fresh visceral examination of rat and rabbit foetuses used in teratogenicity testing. Teratogen Carcinogen Mutagen 4:181-188.
22. Tyl RW, Carr MC. 1996. Developmental toxicity testing: methodology. In: Hood RD, editor. Handbook of developmental toxicology. Boca Raton: CRC Press. p 175-226.
23. Wang S, Vrana JA, Bartimole TM, Freemerman AJ, Jarvis WD, Kramer LB, Krystal G, Dent P, Grant S. 1997. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-h-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2. Mol Pharmacol 52:1000-1009. (Pubitemid 28013718)
24. Wang Z, Wang S, Dai Y, Grant S. 2002. Bryostatin 1 increases 1-h-D-arabinofuranosylcytosine-induced cytochrome c release and apoptosis in human leukemia cellsectopically expressing Bcl-x(L). J Pharmacol Exp Ther 301:568-577.
25. Weitman S, Langevin AM, Berkow RL, Thomas PJ, Hurwitz CA, Kraft AS, Dubowy RL, Smith DL, Bernstein MA. 1999. Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. Clin Cancer Res 5:2344-2348.
26. Zhang X, Zhang R, Zhao H, Cai H, Gush KA, Kerr RG, Pettit GR, Kraft AS. 1996. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Res 56:802-808.